Cancer treatment—residual (R) tumour indicator, yes/no code N

Exported from METEOR (AIHW's Metadata Online Registry)
© Australian Institute of Health and Welfare 2024
This product, excluding the AlHW logo, Commonwealth Coat of Arms and any material owned by a third party or protected by a trademark, has been released under a Creative Commons BY 4.0 (CC BY 4.0) licence. Excluded material owned by third parties may include, for example, design and layout, images obtained under licence from third parties and signatures. We have

made all reasonable efforts to identify and label material owned by third parties.

You may distribute, remix and build on this website's material but must attribute the AlHW as the copyright holder, in line with our attribution policy. The full terms and conditions of this licence are available at https://creativecommons.org/licenses/by/4.0/.

Enquiries relating to copyright should be addressed to info@aihw.gov.au.

Enquiries or comments on the METEOR metadata or download should be directed to the METEOR team at meteor@aihw.gov.au.

Cancer treatment—residual (R) tumour indicator, yes/no code N

Identifying and definitional attributes

Metadata item type: Data Element

Short name: Residual tumour indicator

METEOR identifier: 430267

Registration status: Health, Standard 08/05/2014

Definition: An indicator of whether residual tumour is present after the course of treatment for

cancer, as represented by a code.

Data Element Concept: Cancer treatment—residual (R) tumour indicator

Value Domain: Yes/no code N

Value domain attributes

Representational attributes

Representation class: Code

Data type: Boolean

Format: N
Maximum character length: 1

Value Meaning

Permissible values: 1 Yes

2 No

Source and reference attributes

Submitting organisation: Australian Institute of Health and Welfare

Data element attributes

Collection and usage attributes

Guide for use: Record the presence of residual tumour on completion of the course of treatment

for cancer.

In some cases treated with surgery and/or neoadjuvant therapy, residual tumour will be present at the primary site after treatment because of incomplete resection or

local and regional disease extending beyond the scope of resection.

Collection methods: This information should be sought from the patient's medical record, referral letters

or attending medical clinician.

Comments: The presence of residual tumour may indicate the effect of treatment, influence

further treatment decisions, and be a strong predictor of prognosis.

Source and reference attributes

Submitting organisation: Cancer Australia

Reference documents: American Joint Committee on Cancer 2010. AJCC Cancer Staging Manual, 7th

edition. Springer: New York

Relational attributes

Specifications:

Health, Superseded 14/05/2015

Conditional obligation: This data element is to be recorded for patients with ovarian cancer and stage IV endometrial cancer when surgical treatment for gynaecological cancer has been completed.

Gynaecological cancer (clinical) NBPDS

Health, Standard 14/05/2015

Conditional obligation:

This data element is to be recorded for patients with ovarian cancer and stage IV endometrial cancer when surgical treatment for gynaecological cancer has been completed.

Lung cancer (clinical) DSS

Health, Superseded 14/05/2015

Conditional obligation: Collect when a person with cancer has completed their initial course of cancer treatment.

Lung cancer (clinical) NBPDS

Health, Standard 14/05/2015

Conditional obligation:

Collect when a person with cancer has completed their initial course of cancer treatment.